NCT03082209 - A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

January 21, 2022

Study Completion Date

January 21, 2022

Conditions

Advanced Solid TumorsCancerHematologic Malignancies

Interventions

DRUG

ABBV-621

Intravenous (IV)

DRUG

Venetoclax

tablet, oral

DRUG

Bevacizumab

IV infusion

DRUG

FOLFIRI

IV infusion

Trial Locations (19)

28040

Hospital Universitario Fundacion Jimenez Diaz /ID# 200106, Madrid

28050

Hospital Universitario HM Sanchinarro /ID# 165136, Madrid

48109

Univ Michigan Med Ctr /ID# 207134, Ann Arbor

60426

Ingalls Memorial Hosp /ID# 171221, Harvey

77030

MD Anderson Cancer Center /ID# 202187, Houston

78229

South Texas Accelerated Research Therapeutics /ID# 160574, San Antonio

06510

Yale University /ID# 158029, New Haven

60637-1443

The University of Chicago Medical Center /ID# 158030, Chicago

02903

Rhode Island Hospital /ID# 171157, Providence

37232-0011

Vanderbilt University Medical Center /ID# 215000, Nashville

77090-1243

Millennium Oncology /ID# 214981, Houston

53226-3522

Medical College of Wisconsin /ID# 171152, Milwaukee

277-8577

National Cancer Center Hospital East /ID# 160596, Kashiwa-shi

990-9585

Yamagata University Hospital /ID# 200681, Yamagata

3015 GD

Erasmus Medisch Centrum /ID# 160869, Rotterdam

9713 GZ

Universitair Medisch Centrum Groningen /ID# 169748, Groningen

6229 HX

Maastricht Universitair Medisch Centrum /ID# 214935, Maastricht

3584 CX

Universitair Medisch Centrum Utrecht /ID# 169747, Utrecht

08035

Hospital Universitario Vall d'Hebron /ID# 170809, Barcelona